• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

No significant benefit of long-acting muscarinic antagonists over long-acting beta-agonists in reducing exacerbation risk in uncontrolled, persistent asthma

byQasim HussainiandDaniel Fisher
March 23, 2018
in Chronic Disease, Emergency, Pediatrics, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adjunct long-acting muscarinic antagonist (LAMA) use with corticosteroids was associated with reduced exacerbation risk compared with placebo in patients with uncontrolled, persistent asthma.

2. LAMA, long-acting beta-agonist (LABA), and inhaled corticosteroids (triple therapy) were not associated with lower risk of exacerbations compared to LABA and inhaled corticosteroids alone.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Management of persistent asthma includes the use of daily inhaled corticosteroids (ICS). As disease severity increases, LABAs are added or the dose of ICS increases, but it is unclear what the role for adjunct LAMAs might be. The current study is a systematic review and meta-analysis that analyzed the utility of adding a LAMA as an adjunct therapy to ICS or to ICS and LABA together in patients with uncontrolled, persistent asthma older than 12 years of age. Overall, the addition of a LAMA versus placebo to ICS significantly reduced the risk of exacerbations requiring systemic corticosteroids. However, adding LAMA to ICS did not offer significant improvements in exacerbation risks compared to adding LABA or doubling the dose of ICS. Finally, using LAMA, LABA, and ICS together (triple therapy) was not associated with significant reduction in exacerbation risk.

Overall, the study suggests that while LAMA does significantly reduce the risk of asthma exacerbations compared to placebo, clinical outcomes are similar when compared to adjunct LABA. The study did not consider the harms or costs associated with one treatment over the other, and these may influence clinical practice and treatment decisions. As LAMA (such as tiotropium) is now approved for use in children as young as 6, future studies may evaluate the clinical benefit of treatment with LAMA in this group.

Click to read the study, published in JAMA

RELATED REPORTS

Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease

Relevant Reading: A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.

In-Depth [systematic review]: The current study is a systematic review and meta-analysis that searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. Included studies evaluated patients 12 years and older with uncontrolled, persistent asthma that compared LAMA vs placebo or vs another add-on therapy to ICS or that compared triple therapy (LAMA, LABA and ICS) to ICS and LABA. Progressive increase in asthma symptoms or a decrease in morning peak expiratory flow (PEF) of 30% or more for 2 or more days was defined as an asthma exacerbation. Data synthesis was based on pharmacologic class (LAMA, LABA, or ICS) as opposed to an individual drug. Overall, 15 randomized clinical trials (N = 7122 patients) were identified. Adjunct LAMA, compared to a placebo, demonstrated significant reduction in asthma exacerbation (RR, 0.67 [95% CI, 0.48 to 0.92]. When compared to adjunct LABA, adjunct LAMA did not offer significant benefits in reducing risk of asthma exacerbation (RR, 0.83 [95% CI, 0.53 to 1.42] or other outcomes of interest. Triple therapy was not associated with significant reduction in asthma exacerbation risk (RR, 0.84 [95% CI, 0.57 to 1.22].

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmacorticosteroids
Previous Post

Racial/ethnic disparities in cardiovascular health persist in U.S. adults

Next Post

Accountable Care Organizations linked to modest increase in appropriate cancer screening

RelatedReports

Teen asthma controller medication adherence affected by risk tolerance
Chronic Disease

Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma

March 4, 2025
2 Minute Medicine Rewind May 20, 2019
Pharma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

January 20, 2025
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease

January 7, 2025
Chronic Disease

Asthma may be associated with impaired memory function in children

November 21, 2024
Next Post
Spiculation of breast masses seen on mammography represents adipose invasion

Accountable Care Organizations linked to modest increase in appropriate cancer screening

Multicomponent nonpharmacological delirium intervention reduced delirium, falls

Medicare's condition-specific readmission measures are poor reflectors of hospital quality

Financial incentive programs significantly improve smoking cessation

E-cigarette use may hamper smoking cessation for smokers planning to quit post-hospitalization

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
  • #VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.